Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 Aug;166(15):1571-7.
doi: 10.1001/archinte.166.15.1571.
Affiliations
- PMID: 16908789
- DOI: 10.1001/archinte.166.15.1571
Randomized Controlled Trial
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
Cheryl Oncken et al. Arch Intern Med. 2006 Aug.
Abstract
Background: The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety, and tolerability of 4 varenicline dose regimens, 2 with progressive dosing over the first week (eg, titrated) and 2 with a fixed dosing schedule (eg, non-titrated), for promoting smoking cessation.
Methods: This multicenter, double-blind, placebo-controlled study randomized healthy smokers (aged 18-65 years) to varenicline tartrate, 0.5 mg twice daily nontitrated (n = 129), 0.5 mg twice daily titrated (n = 130), 1.0 mg twice daily nontitrated (n = 129), 1.0 mg twice daily titrated (n = 130), or placebo (n = 129) for 12 weeks to aid in smoking cessation. A 40-week follow-up period assessed long-term efficacy. The primary efficacy measures were the carbon monoxide-confirmed 4-week continuous quit rates by pooled dosage group for weeks 4 through 7 and 9 through 12 and the continuous abstinence rates for weeks 9 through 52.
Results: Weeks 9 through 12 continuous quit rates were greater in the 1.0-mg group (49.4%) and the 0.5-mg group (44.0%) vs placebo (11.6%; P<.001 vs both doses). Weeks 9 through 52 abstinence rates were greater in the 1.0-mg group (22.4%; P<.001) and the 0.5-mg group (18.5%; P<.001) vs placebo (3.9%). Varenicline was generally well tolerated, with nausea occurring in 16% to 42% of varenicline-treated subjects. Reports of nausea were lower for the titrated vs nontitrated dosing and infrequently led to medication discontinuation.
Conclusion: Varenicline tartrate, 0.5 mg and 1.0 mg twice daily, is efficacious for smoking cessation.
Comment in
- New weapon to curb smoking: no more excuses to delay treatment.
Johnson BA. Johnson BA. Arch Intern Med. 2006 Aug 14-28;166(15):1547-50. doi: 10.1001/archinte.166.15.1547. Arch Intern Med. 2006. PMID: 16908786 No abstract available. - Partial agonism at nicotinic receptors with varenicline--a new approach to smoking cessation.
Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2006 Dec;7(18):2599-603. doi: 10.1517/14656566.7.18.2599. Expert Opin Pharmacother. 2006. PMID: 17150012 No abstract available.
Similar articles
- Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR. Nides M, et al. Arch Intern Med. 2006 Aug 14-28;166(15):1561-8. doi: 10.1001/archinte.166.15.1561. Arch Intern Med. 2006. PMID: 16908788 Clinical Trial. - Varenicline for smoking cessation: a placebo-controlled, randomized study.
Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Wang C, et al. Respirology. 2009 Apr;14(3):384-92. doi: 10.1111/j.1440-1843.2008.01476.x. Epub 2009 Feb 20. Respirology. 2009. PMID: 19192221 Clinical Trial. - Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
Lam S, Patel PN. Lam S, et al. Cardiol Rev. 2007 May-Jun;15(3):154-61. doi: 10.1097/01.crd.0000260270.12829.45. Cardiol Rev. 2007. PMID: 17438382 Review. - Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, Park PW, Chopra P. Bolliger CT, et al. Clin Ther. 2011 Apr;33(4):465-77. doi: 10.1016/j.clinthera.2011.04.013. Clin Ther. 2011. PMID: 21635992 Clinical Trial. - Varenicline in smoking cessation.
Tonstad S, Rollema H. Tonstad S, et al. Expert Rev Respir Med. 2010 Jun;4(3):291-9. doi: 10.1586/ers.10.27. Expert Rev Respir Med. 2010. PMID: 20524911 Review.
Cited by
- Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.
Harmey D, Griffin PR, Kenny PJ. Harmey D, et al. Nicotine Tob Res. 2012 Nov;14(11):1300-18. doi: 10.1093/ntr/nts201. Epub 2012 Sep 27. Nicotine Tob Res. 2012. PMID: 23024249 Free PMC article. Review. - Paecilomycies japonica reduces repeated nicotine-induced neuronal and behavioral activation in rats.
Ye M, Lee H, Bae H, Hahm DH, Lee HJ, Shim I. Ye M, et al. BMC Complement Altern Med. 2015 Jul 14;15:227. doi: 10.1186/s12906-015-0739-8. BMC Complement Altern Med. 2015. PMID: 26169054 Free PMC article. - Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century.
Laniado-Laborín R. Laniado-Laborín R. Int J Environ Res Public Health. 2009 Jan;6(1):209-24. doi: 10.3390/ijerph6010209. Epub 2009 Jan 9. Int J Environ Res Public Health. 2009. PMID: 19440278 Free PMC article. Review. - Targeting nicotine addiction: the possibility of a therapeutic vaccine.
Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM. Escobar-Chávez JJ, et al. Drug Des Devel Ther. 2011;5:211-24. doi: 10.2147/DDDT.S10033. Epub 2011 Apr 18. Drug Des Devel Ther. 2011. PMID: 21607018 Free PMC article. Review. - Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo-controlled studies of varenicline.
Tonstad S, Lawrence D. Tonstad S, et al. J Diabetes Investig. 2017 Jan;8(1):93-100. doi: 10.1111/jdi.12543. Epub 2016 Jul 14. J Diabetes Investig. 2017. PMID: 27223809 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical